Tocilizumab, risk of intubation and survival in patients with COVID-19 pneumonia

https://doi.org/10.36109/rmg.v161i2.466
Pneumonia Coronavirus Infections Immunomodulator COVID-19

Authors

  • Maynor Palma
    Enfermedadesrespiratorias@outlook.com
    Unidad de Neumología, Hospital Roosevelt, Guatemala, Guatemala., Guatemala
  • Edgar Contreras Unidad de Neumología, Hospital Roosevelt, Guatemala, Guatemala., Guatemala
  • Johanna Samayoa Unidad de Infectología, Hospital Roosevelt, Guatemala, Guatemala., Guatemala
  • Anabella de Wyss Departamento de Farmacia Interna, Hospital Roosevelt, Guatemala, Guatemala., Guatemala
Vol. 161 No. 2: April - June, 2022
Artículos Originales
January 11, 2022
June 9, 2022

Coronavirus Disease 2019 (COVID-19) causes pneumonia that requires treatment with Tocilizumab (TCZ). There is little information from the TCZ on the Guatemalan population. Objective: to describe the association of TCZ with the risk

How to Cite

Tocilizumab, risk of intubation and survival in patients with COVID-19 pneumonia. (2022). Revista médica (Colegio De Médicos Y Cirujanos De Guatemala), 161(2), 118-123. https://doi.org/10.36109/rmg.v161i2.466